KALARIS THERAPEUTICS, INC. Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months
KALARIS THERAPEUTICS, INC. (KLRS) had Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months of $0 as of 2025-12-31, per its 10-K filed 2026-03-17.
Financial Statements › Notes › Debt and Equity Securities › Debt Securities, Available-for-Sale, Unrealized Loss Position
us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months · last filed 2026-03-17
- 2025-12-31: Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months $0.00.
- 2025-09-30: Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months $9.80M.
| Period end | Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months |
|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-03-17 |
| 2025-09-30 | $9.80M 10-Q · filed 2025-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |